Quick Answer
INOVIO PHARMACEUTICALS, INC. reported Research And Development Expense of $54.21 million for the year ending 2025.
- INOVIO PHARMACEUTICALS, INC. showed a decrease of -28.3% in Research And Development Expense from 2024 to 2025.
- This data is from INOVIO PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), INOVIO PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 476.2%.
- Historical annual values: Fiscal year 2025: $54.21 million | Fiscal year 2024: $75.62 million | Fiscal year 2023: $86.68 million | Fiscal year 2022: $187.65 million | Fiscal year 2021: $249.24 million | Fiscal year 2020: $94.25 million | Fiscal year 2019: $88.02 million | Fiscal year 2018: $95.26 million | Fiscal year 2017: $98.57 million | Fiscal year 2016: $88.71 million | Fiscal year 2015: $57.79 million | Fiscal year 2014: $34.10 million | Fiscal year 2013: $21.37 million | Fiscal year 2012: $17.98 million | Fiscal year 2011: $20.03 million | Fiscal year 2010: $13.26 million | Fiscal year 2009: $9.41 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: